Studies are a great way to prove and show the efficacy and sometimes diversity of an ingredient in the world of health, sports, and lifestyle nutrition. Under controlled conditions, they can give companies the ability to make research-backed claims and communicate what exactly something is designed to do and deliver. They are a massive undertaking by those who go through the effort of getting it done, and here today, we’re highlighting one from FutureCeuticals regarding CognatiQ.
FutureCeuticals’ latest scientific study, published in Nutrients, validates the cognitive performance benefits of CognatiQ in a groundbreaking remote clinical trial. Conducted with a diverse group of healthy subjects aged 40-65 across the United States, the study challenged traditional laboratory settings by mimicking real-life conditions. Results showed that a single 200mg dose of CognatiQ significantly improved cognitive performance just one-hour post-ingestion, particularly impacting working memory, which is crucial for reasoning, comprehension, and decision-making.
The study demonstrated CognatiQ’s ability to enhance focus, accuracy, and concentration while alleviating and reducing mental fatigue. The participants experienced notable efficacy improvements ranging from 25% to 80% in various cognitive measures. The study not only replicates previous laboratory results but also extends them to real-world scenarios, providing strong evidence that CognatiQ’s effects on cognitive performance are not limited to controlled environments.
CognatiQ, previously called NeuroFactor, can be found in all sorts of sports nutrition supplements, including pre-workouts, nootropics, and even an energy drink by way of Ghost’s hugely popular beverage, the Ghost Energy Drink. The new FutureCeuticals study further justifies the position and purpose of the ingredient, as those specific types of products do require fast-acting and noticeably effective focus and cognitive enhancement, which the CognatiQ study reflects.
